SCHEMBL633305

SCHEMBL633305

CCC(=O)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TPMT P51580 1/20 0.52
RAB9A P51151 1/20 0.46
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PPARA Q07869 2/20 0.41
HCAR1 Q9BXC0 1/20 0.40
MEN1 O00255 1/20 0.40
CYP3A4 P08684 1/20 0.40
PTGS1 P23219 1/20 0.40
DRD3 P35462 1/20 0.40
KMT2A Q03164 1/20 0.40
ATM Q13315 1/20 0.40
GRN P28799 2/20 0.40
SORT1 Q99523 2/20 0.40
BRD4 O60885 1/20 0.39
BAZ2B Q9UIF8 1/20 0.39
BAZ2A Q9UIF9 1/20 0.39
FABP4 P15090 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1260276 0.87 HCAR1 (0.59) TPMTRAB9AMAPTSMN1; SMN2L3MBTL1
SCHEMBL19137597 0.87 GPR139 (0.42) TPMTRAB9AMAPTSMN1; SMN2L3MBTL1
SCHEMBL11342136 0.87 TSHR (0.42) TPMTRAB9AMAPTSMN1; SMN2L3MBTL1
SCHEMBL12780435 0.86 TAS1R3 (0.43) TPMTRAB9AMAPTSMN1; SMN2L3MBTL1
SCHEMBL30512212 0.86 TAS1R3 (0.43) TPMTRAB9AMAPTSMN1; SMN2L3MBTL1
SCHEMBL27915406 0.82 DDR1 (0.46) SMN1; SMN2MEN1KMT2ABAZ2BBAZ2A
SCHEMBL11382828 0.82 MAPT (0.50) MAPTSMN1; SMN2L3MBTL1PPARAMEN1
SCHEMBL10412858 0.81 TPMT (0.35) TPMTRAB9AMAPTSMN1; SMN2L3MBTL1
SCHEMBL27873685 0.81 DDR1 (0.48) PPARAMEN1CYP3A4KMT2AGAA
SCHEMBL28277550 0.79 PPARA (0.47) MAPTSMN1; SMN2L3MBTL1PPARAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111212830-B N- (substituted sulfonyl) benzamide derivative and preparation method and medical application thereof 浙江海正药业股份有限公司 2023-07-04 CN disclosed
CN-113234062-B Pyrazinylimidazole compound, weldable protective agent, preparation method and application of pyrazinylimidazole compound and weldable protective agent 赣州市贝加尔电子材料有限公司 2022-07-08 CN disclosed
CN-113234062-A Pyrazinylimidazole compound, weldable protective agent, preparation method and application of pyrazinylimidazole compound and weldable protective agent 赣州市贝加尔电子材料有限公司 2021-08-10 CN disclosed
US-10919841-B2 Monoamine reuptake inhibitors RESEARCH TRIANGLE INSTITUTE (US) 2021-02-16 US disclosed
CN-111212830-A N- (substituted sulfonyl) benzamide derivative and preparation method and medical application thereof 浙江海正药业股份有限公司 2020-05-29 CN disclosed
CN-106165684-B Pesticidal compositions and methods relating thereto 陶氏益农公司 2019-06-14 CN disclosed
CN-105153235-B Phosphor material 通用显示公司 2019-05-10 CN disclosed
WO-2019062848-A1 N-(SUBSTITUTED SULFONYL)BENZAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF 浙江海正药业股份有限公司 2019-04-04 WO disclosed
CN-105025715-B Pesticidal compositions and methods related thereto 美国陶氏益农公司 2018-11-16 CN disclosed
CN-108495851-A Substituted benzamide and its application method 基因泰克公司 2018-09-04 CN disclosed
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 US disclosed
EP-2419400-A1 MONOAMINE REUPTAKE INHIBITORS RESEARCH TRIANGLE INSTITUTE (US) 2012-02-22 EP disclosed
US-20120020920-A1 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-01-26 US disclosed
WO-2011146821-A2 1 - PHENYLMORPHOLINE DERIVATIVES AS HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE RESEARCH TRIANGLE INSTITUTE (US) 2011-11-24 WO disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 US disclosed
WO-2010121022-A1 MONOAMINE REUPTAKE INHIBITORS RESEARCH TRIANGLE INSTITUTE (US) 2010-10-21 WO disclosed
CN-101657518-A phosphorescent material UNIV DISPLAY CORP US 2010-02-24 CN disclosed
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
CN-1063440-C Process for the desulfurization and the desalting of fossil fuels RHONE ROULENC AGROCHIMIE CORP (FR) 2001-03-21 CN disclosed
CN-1079735-A Arylpyrazole mycocide ENERGY BIOSYSTEMS CORP (FR) 1993-12-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120020920-A1 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR GTF3C5, ZC3HAV1, POLI TPMT 132/4885RAB9A 1530/4885MAPT 4033/4885
US-10919841-B2 Monoamine reuptake inhibitors SLC6A2, SLC6A4, SLC6A3 TPMT 1838/4885RAB9A 2855/4885MAPT 440/4885
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR POLI, TERT, ZC3HAV1 TPMT 33/4885RAB9A 2410/4885MAPT 3389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.